Evidence map›Paper›PMID 35757141›Full record

ArticleFrontiers in pediatrics2022

Cardiac Manifestations of Myotonic Dystrophy in a Pediatric Cohort.

Laia Brunet Garcia, Ankita Hajra, Ella Field, Joseph Wacher, Helen Walsh, Gabrielle Norrish, Adnan Manzur, Francesco Muntoni, Pinki Munot, Stephanie Robb and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Laia Brunet GarciaHospital de Mataró, Barcelona, Spain.
Ankita HajraGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Ella FieldGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Joseph WacherGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Helen WalshGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Gabrielle NorrishGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Adnan ManzurGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Francesco MuntoniGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Pinki MunotGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Stephanie RobbGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Rosaline QuinlivanGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Mariacristina ScotoGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Giovanni BaranelloGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Anna SarkozyGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Luke StarlingGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Juan Pablo KaskiGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Elena CerviGreat Ormond Street Hospital Children's Charity, London, United Kingdom.
Great Ormond Street Hospital Children's Charity · GBHospital de Mataró · ES

Funding

Medical Research Council MR/T024062/1
6 · The paper itself

Abstract

Myotonic dystrophy type 1 (DM1) is the most prevalent inherited neuromuscular dystrophy in adults. It is a multisystem disease with cardiac manifestations. Whilst these are well-defined in adults, there are scarce published data in the pediatric population. This study aimed to investigate the yield and progression of cardiac disease in pediatric DM1 patients, focusing on congenital DM1 (cDM1). Methods: A retrospective observational study of all pediatric DM1 patients referred to our center (December 2000-November 2020) was conducted. Patients were classified into DM1 forms according to age of symptom onset and disease severity. Patients underwent clinical and cardiac evaluation with 12-lead ECG, transthoracic echocardiography and 24-h ECG Holter monitoring. Results: 67 DM1 pediatric patients were included: 56 (83.6%) cDM1 and 11 (16.4%) non-cDM1. Median follow-up time of cDM1 patients was 8.0 [3.25-11.0] years. 49 (87.5%) cDM1 patients had baseline 12-lead ECG and 44 (78.6%) had a follow-up 12-lead-ECG, with a median follow-up time from diagnosis to baseline ECG of 2.8 [1.0-8.5] years and to follow-up ECG of 10.9 [5.7-14.2] years. Overall, 43 (87.8%) presented ECG abnormalities, most commonly in the form of asymptomatic conduction disease ( Conclusions: This study is the first to analyse the prevalence and progression of ECG abnormalities in cDM1 pediatric patients. The high prevalence of abnormal findings, progressive changes and number of potentially associated events (1 pacemaker implantation and 3 unexplained sudden deaths) stresses the importance of systematic and continued cardiac evaluation of these patients.

Indexed as

cardiac conduction diseasecongenital myotonic dystrophyelectrocardiographic abnormalitiesmyotonic dystrophy (DM1)neuromuscular disorderpediatric population

Identifiers

PMID35757141
PMCPMC9218560
OpenAlexW4285743236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.